Same Score, Different Risk: Toward Individualized Anticoagulation After Successful AF Ablation: A Narrative Review for the Post-Ablation Antithrombotic Decision in Atrial Fibrillation

Current guidelines recommend that long-term oral anticoagulation (OAC) after atrial fibrillation (AF) ablation be guided by CHA2DS2-VASc rather than ablation success. However, two recent randomized trials, ALONE-AF and OCEAN, observed very low stroke and systemic embolism rates in rigorously selected post-ablation populations. Because events were rare and neither trial was powered for noninferiority for stroke, they do not definitively establish equivalence with continued OAC. Integrating these data with AF burden studies, atrial cardiomyopathy research, and post-ablation registries, we examine the hypothesis that a given CHA2DS2-VASc score may confer lower stroke risk when AF burden is durably suppressed. We identify five domains clinicians should weigh: time since ablation, monitoring quality, AF burden, atrial substrate, and baseline thromboembolic risk. Within patients with 1–2 non-sex CHA2DS2-VASc risk factors, arrhythmia-free beyond 12 months with robust monitoring, and without advanced atrial cardiomyopathy, the discussion of OAC de-escalation can now be informed by randomized data rather than extrapolation alone. We also identify the uncertainties that remain and the populations in whom guideline-directed OAC remains the standard of care.